Cellipont Bioservices
Mike O'Mara has extensive experience in the biotechnology and pharmaceutical industry. Mike currently serves as the Chief Operating Officer at Cellipont Bioservices, starting in March 2022. Prior to this, they held various leadership roles at Miltenyi Biotec, including VP of BioIndustry and Vice President of Industrial Business Services from April 2020 to January 2022. From November 2016 to April 2020, Mike was the Senior Vice President of Manufacturing Operations at Cytovance Biologics. Mike also served as the Senior Director of Manufacturing, Testing and Technical Services at DynPort Vaccine Company LLC, A CSRA Company, from November 2014 to November 2016. Before that, they were the Vice President of Manufacturing at TissueGene from March 2013 to November 2014. Mike started their career at BioScience Contract Production Corp. in October 1995 as a Fermentation Supervisor and gradually moved up the ranks in companies like Cambrex BioScience Baltimore and Cambrex before joining Lonza in September 2008. At Lonza, they held various positions including Director of Manufacturing Sciences and Technology, Director of Operations, and Head of Manufacturing. Mike also briefly worked as a Biopharmaceutical Contractor/Consultant at Aerotek in December 2012 before joining Miltenyi Biotec. Overall, Mike O'Mara has developed a strong expertise in manufacturing operations and has held key leadership positions in renowned biotech companies.
Mike O'Mara attended the University of Maryland from 1992 to 1995, where they pursued a Bachelor of Science degree in Microbiology. Additionally, from 1993 to 1995, they also enrolled in the University of Maryland Global Campus to further their studies in Microbiology.
Cellipont Bioservices
Cellipont Bioservices is a cell therapy CDMO with more than 15 years’ experience in the development and small-to-large batch manufacturing of cell therapies. Our leaders have played an instrumental role in shaping cell therapy development and manufacturing methods and technologies, and our technically-strong team has been recognized by customers and technology partners for its ability to productively grow challenging cells. Cellipont is driven to help our clients to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. We are a small company with a culture that is extremely responsive and customer-centric. Despite our size, Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 900 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont’s growth with deep knowledge of what it takes succeed in this space. Cellipont Bioservices facilities and quality systems are GMP-compliant and we hold a California Food & Drug Branch manufacturing license. We have extensive experience in multiple product areas, including CAR-T, iNK, dendritic cell, & other novel cell therapy approaches. OUR NAME: By combining “cell” with the latin root for bridge (pont), the name Cellipont Bioservices reflects several dimensions of what we are all about: we bridge our innovator clients with patients; we bridge technical excellence and personal service; and for our team, we bridge personal passion with professional vocation. As we finalize our corporate rebranding, we look forward to launching a new website in the coming weeks to better share our vision with you.